Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study

Table 1 Baseline demographic and clinical characteristics

Characteristic	Patients (n = 30)
Age, years	63.0 (40–78)
Male, n (%)	15 (50)
Time since diagnosis, years	5.5 (0.2^a–22.2)
Prior treatment for NETs, n (%)
Surgery	23 (76.7)
Any systemic antineoplastic therapy	15 (50.0)
Chemotherapy^b	10 (33.3)
Interferon^b	7 (23.3)
Somatostatin analogues^c	6 (20.0)
Radiotherapy^b	1 (3.3)
Origin of NETs, n (%)
Gastroenteropancreatic NETs
Pancreas	8 (26.7)
Stomach	1 (3.3)
Small intestine	10 (33.3)
Large intestine	3 (10.0)
Bronchopulmonary NETs
Bronchus	4 (13.3)
Unknown	4 (13.3)
Tumour functionality, n (%)
Functioning	19 (63.3)
Carcinoid tumour	18 (60.0)
Gastrinoma	1 (3.3)
Non-functioning	11 (36.7)
Symptomatic	9 (30.0)
Chromogranin A, μg/L	332.5 (44.1–66,056.0)
Urinary 5-HIAA, μmol/d	114.0 (19.9–1684.1)
Ki-67 index
Ki-67 ≤2%	13 (43.3)
Ki-67 >2%	8 (26.7)
Not evaluated	9 (30.0)
Performance status: ECOG grade, n (%)
0	19 (63.3)
1	9 (30.0)
2	2 (6.7)

Data are median (range) unless stated otherwise for quantitative parameters.
5-HIAA, 5-hydroxyindoleacetic acid; ECOG, Eastern Cooperative Oncology Group; NETs, neuroendocrine tumours.
^aThe patient diagnosed 0.2 years before the study (and thus apparently non-compliant with inclusion criteria) had had an earlier misdiagnosis (2 years previously) of vertebral haemangioma that should have been NET metastases.
^bPatients who received treatment with radiotherapy, chemotherapy or interferon within 4 weeks prior to study inclusion or who were scheduled to receive it during the study were excluded from the study.
^cPatients who received treatment with somatostatin analogues within 6 months prior to study inclusion were excluded from the study.

ISSN: 1471-2407